Israeli Scientists Claim Multiple-Attack Drug Cures Cancer, Will Be Ready in 1 Year

January 31, 2019 Updated: January 31, 2019

It has been at the forefront of medical research for the last century: finding a cure for cancer. And it looks as though 2019 will be a colossal year for progress.

Within the year, a “complete cure for cancer” will be made available, scientists claim. Can we believe it? We need to believe in something, given that an estimated 18.1 million new cancer cases are diagnosed worldwide every year.

A team of Israeli scientists claim to have found the cure for cancer (Illustration – Shutterstock | Gorodenkoff)

What follows is the fine print.

The Jerusalem Post reported that a team of Israeli scientists working on behalf of Accelerated Evolution Biotechnologies Ltd. (AEBi) have worked together to produce what seems to be an effective cure for the devastating disease. The team has stated that their cure “will be effective from day one.” We won’t have to wait long to find out, as the treatment should be released within the next 12 months.

The treatment is being referred to as “MuTaTo” (multi-target toxin) and will function in the same manner as an antibiotic to treat destructive cancer cells. Company CEO Dr. Ilan Morad explained that the treatment will employ a combination of cancer-targeting peptides and a toxin aimed specifically at the cancer cells.

Cancer stem cell research in the laboratory (Illustration – Shutterstock | science photo)

In conversation with The Jerusalem Post, company chairman Dan Aridor explained further:

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market.”

Readers may feel incredulous, as the battle against cancer is one that has been fought particularly long and hard, and has personal resonance with millions upon millions of people. So why is this treatment so different?

The AEBi science team initially tried to copy previous models, but it wasn’t long before they realized that they had to approach the problem from a different angle.

They turned the question of a cure for cancer in on itself.

Why were other cancer-killing drugs and treatments failing? The team took a scrupulous look at the details of past failures. Next, they turned towards considering all possible solutions.

CEO Ilan Morad went on to describe how most anti-cancer drugs used in current treatments attack a specific target. They fail because the target mutates and is no longer vulnerable to attack.

MuTaTo will work differently to its predecessors (Illustration – Shutterstock | crystal light)

MuTaTo, so the science team says, will not fail in this way. The treatment will deploy a multiple-attack on the cells, instead essentially a “safety-in-numbers” approach to eradicating destructive cancer cells. Cancer-targeting peptides will function alongside a strong peptide toxin that will specifically hone in on, and kill, targeted cancer cells.

Mutants beware: this multi-directional attack will render the previous defense mechanism, mutating to avoid attack, completely useless.

A multi-directional attack will prevent cancer cell mutation (Illustration – Shutterstock | fusebulb)

“Instead of attacking receptors one at a time, we attack receptors three at a time—not even cancer can mutate three receptors at the same time,” Morad assured.

Morad equated MuTaTo’s principles to the triple drug cocktail that has rendered AIDS a manageable disease. Previously, AIDS carried a terminal prognosis.

So far, so impressive. But what about the side-effects?

This new approach could seriously reduce side-effects, the team claims. Morad even goes on to say that the drug will be personalised to each patient, in good time and within reason.

But here comes the sting: so far, the company has only conducted its experiments on mice. Human trials are both legally mandatory and ethically necessary before the drug can be released onto the treatment market.

We have high hopes for the science behind the medicine. But as for its efficacy, human trials may take a few years to complete. The Jerusalem Post announced that AEBi is on the cusp of beginning a round of clinical trials.

We will just have to hope, wait, and see.

Do you have faith in this new cure for cancer? Be sure to share this article, and share your thoughts with us in the comments below!

Recommended